A critical appraisal of the prognostic utility of four separate immunocytochemical markers (somatostatin, gastrin-releasing peptide, neuropeptide Y, and opioid peptides) in sporadic medullary thyroid carcinoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 5, Issue 1, 1997, Pages 23-28

  Scopsi, Lucio ^a,b   Sampietro, Giuseppe ^a   Boracchi, Patrizia ^a   Pilotti, Silvana ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE   (Italy)

Author keywords

Immunocytochemistry; Prognosis; Regulatory peptides; Somatostatin; Thyroid cancer; Thyroid medullary carcinoma

Indexed keywords

GASTRIN RELEASING PEPTIDE; NEUROPEPTIDE Y; OPIATE PEPTIDE; SOMATOSTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; THYROID MEDULLARY CARCINOMA;

EID: 0030913601     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-199703000-00004     Document Type: Article

References (39)

1. Scopsi L. Non-calcitonin gene-derived neurohormonal polypeptides in normal and pathologic thyroid C cells. Prog Surg Pathol 1990;11:185-229.
2. Scopsi L. Peptide regulatory factors in the thyroid C cell system: an updating. In: Calmettes C, Guliana JM, eds. Medullary thyroid carcinoma. Paris: John Libbey Eurotext Ltd., 1991:95-8 (Colloque INSERM, vol. 211).
3. Ahren B. Regulatory peptides in the thyroid gland: a review on their localization and function. Acta Endocrinol 1991;124:225-32.
4. Grauer A, Schroth J, Ziegler R, Raue F. Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma. Thyroid 1995;5:287-91.
5. Mekonnen Y, Raue F, Zink A, Ziegler R. Long-term exposure to SMS 201-995 inhibits proliferation and calcitonin release in neoplastic C-cells. Horm Metab Res 1992;25:528-31.
6. Neonakis E, Thomas GA, Davies HG, Wheeler MH, Williams ED. Expression of calcitonin and somatostatin peptide and mRNA in medullary thyroid carcinoma. World J Surg 1994;18:588-93.
7. Ouazzani L, Reubi JC, Volle GE, et al. Evaluation of somatostatin biosynthesis, somatostatin receptors and tumor growth in murine medullary thyroid carcinoma. Eur J Endocrinol 1994;131:522-30.
8. Pacini F, Elisei R, Anelli S, Basolo F, Cola A, Pinchera A. Somatostatin in medullary thyroid cancer: in vitro and in vivo studies. Cancer 1989;63:1189-95.
9. Pacini F, Basolo F, Elisei R, Fugazzola L, Cola A, Pinchera A. Medullary thyroid cancer: an immunohistochemical and humoral study using six separate antigens. Am J Clin Pathol 1991;95: 300-8.
10. Peiro G, Oliva E, Cabezas R, Matias-Guiu X, Pons C, Prat J. Medullary carcinoma of the thyroid (MCT): clinical and immunohistochemical findings in 20 cases. Patología 1992;25:81S.
11. Scopsi L, Ferrari C, Pilotti S, et al. Immunocytochemical localization and identification of prosomatostatin gene products in medullary carcinoma of human thyroid gland. Hum Pathol 1990;21: 820-30.
12. Weber CJ, Marvin M, Krekun S, et al. Effects of tamoxifen and somatostatin analogue on growth of human medullary, follicular, and papillary thyroid carcinoma cell lines: tissue culture and nude mouse xenograft studies. Surgery 1990;108:1065-71.
13. Scopsi L, Sampietro G, Boracchi P, et al. Multivariate analysis of prognostic factors in patients with sporadic medullary carcinoma of the thyroid: a retrospective study of 109 consecutive patients. Cancer 1996;78:2173-83.
14. Frigo B, Scopsi L, Patriarca C, Rilke F. Silver enhancement of nickel-diaminobenzidine as applied to single and double immunoperoxidase staining. Biotech Histochem 1991;1:159-66.
15. Scopsi L, Arias J, Houen G, Racchetti G, Fossati GL, Galante YM. Monoclonal antibodies against calcitonin: characterization and application in light and electron microscopy immunocytochemistry. Histochemistry 1988;88:113-25.
16. Larsen PJ, Saermark T, Mikkelsen JD. An immunohistochemical demonstration of gastrin-releasing peptide (GRP) in the rat substantia nigra. J Chem Neuroanat 1989;2:83-93.
17. Scopsi L, Pilotti S, Rilke F. Immunocytochemical localization and identification of members of the pancreatic polypeptide (PP)-fold family in human thyroid C cells and medullary carcinomas. Regul Pept 1990;30:89-104.
18. Scopsi L, Balslev E, Brunner N, et al. Immunoreactive opioid peptides in human breast cancer. Am J Pathol 1989;134:473-9.
19. Spiessl B, Beahrs OH, Hermanek P, et al. TNM atlas: illustrated guide to TNM/pTNM classification of malignant tumors, 3rd ed. Berlin: Springer-Verlag, 1992.
20. Fleiss JL. Statistical methods for rates and proportions, 2nd ed. New York: Wiley & Sons Inc., 1981.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
22. Landis JR, Kock GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
23. Reubi JC, Chayvialle JA, Franc B, Cohen R, Calmettes C, Modigliani E. Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. Lab Invest 1991;64:567-73.
24. Frank-Raue K, Ziegler R, Raue F. The use of octreotide in the treatment of medullary thyroid carcinoma. Horm Metab Res Suppl Ser 1993;27:44-7.
25. Modigliani E, Cohen R, Joannidis S, et al. Results of long-term continuous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 1992;36:183-6.
26. Cuttitta F, Carney DC, Mulshine J, et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985;316:823-6.
27. Ghatei MA, Springall DR, Nicholl CG, Polak JM, Bloom SR. Gastrin-releasing peptide-like immunoreactivity in medullary thyroid carcinoma. Am J Clin Pathol 1985;84:581-6.
28. Kameya T, Bessho T, Tsumuraya M, et al. Production of gastrin-releasing peptide by medullary carcinoma of the thyroid. Virchows Arch A Pathol Anat Histopathol 1983;401:99-108.
29. Matsubayashi S, Yanaihara C, Ohkubo M, et al. Gastrin-releasing peptide immunoreactivity in medullary thyroid carcinoma. Cancer 1984;53:2472-7.
30. Modigliani E, Casanova S, Chayvialle JA, et al. Immunoreactive gastrin-releasing peptide in medullary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:831-5.
31. Sunday ME, Wolfe HJ, Roos BA, Chin WW, Spindel ER. Gastrin-releasing peptide gene expression in developing, hyperplastic, and neoplastic human thyroid C-cells. Endocrinology 1988;122: 1551-8.
32. Mansson B, Ahren B, Nobin A, Bottcher G, Sundler F. Calcitonin, calcitonin gene-related peptide, and gastrin-releasing peptide in familial thyroid medullary carcinoma. Surgery 1990;107:182-6.
33. O'Hare MMT, Schwartz TW. Expression and precursor processing of neuropeptide Y in human and murine neuroblastoma and pheochromocytoma cell lines. Cancer Res 1989;49:7015-9.
34. Allen JM, Yeats JC, Causon R, Brown MJ, Bloom SR. Neuropeptide Y and its flanking peptide in human endocrine tumors and plasma. J Clin Endocrinol Metab 1987;64:1199-204.
35. Grouzmann E, Comoy E, Bohuon C. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. J Clin Endocrinol Metab 1989;68:808-13.
36. Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD, Bensch KG. Expression of opioid peptides in tumors. N Engl J Med 1987; 317:1439-43.
37. Ohashi M, Yanase T, Fujio N, Ibayashi H, Kinjio M, Matsuo H. Alfa-neoendorphin-like immunoreactivity in medullary carcinoma of the thyroid. Cancer 1987;59:277-80.
38. Roth KA, Bensch KG, Hoffman AR. Characterization of opioid peptides in human thyroid medullary carcinoma. Cancer 1987;59: 1594-8.
39. Mendelsohn G. Markers as prognostic indicators in medullary thyroid carcinoma. Am J Clin Pathol 1991;95:297-8.